全文获取类型
收费全文 | 259篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 5篇 |
基础医学 | 16篇 |
口腔科学 | 5篇 |
临床医学 | 52篇 |
内科学 | 77篇 |
皮肤病学 | 4篇 |
神经病学 | 14篇 |
特种医学 | 23篇 |
外科学 | 18篇 |
综合类 | 6篇 |
预防医学 | 27篇 |
眼科学 | 1篇 |
药学 | 8篇 |
肿瘤学 | 7篇 |
出版年
2021年 | 2篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 7篇 |
2013年 | 3篇 |
2012年 | 3篇 |
2011年 | 5篇 |
2010年 | 6篇 |
2009年 | 11篇 |
2008年 | 11篇 |
2007年 | 6篇 |
2006年 | 7篇 |
2005年 | 4篇 |
2004年 | 2篇 |
2003年 | 3篇 |
2000年 | 4篇 |
1999年 | 9篇 |
1998年 | 11篇 |
1997年 | 9篇 |
1996年 | 13篇 |
1995年 | 8篇 |
1994年 | 16篇 |
1993年 | 10篇 |
1991年 | 2篇 |
1989年 | 5篇 |
1988年 | 11篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1981年 | 7篇 |
1980年 | 5篇 |
1977年 | 2篇 |
1976年 | 6篇 |
1975年 | 2篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1971年 | 5篇 |
1969年 | 2篇 |
1965年 | 3篇 |
1963年 | 4篇 |
1962年 | 2篇 |
1956年 | 2篇 |
1945年 | 1篇 |
1939年 | 1篇 |
1938年 | 1篇 |
1927年 | 1篇 |
排序方式: 共有278条查询结果,搜索用时 15 毫秒
81.
Upper Limit Ventricular Stimulation in Respiratory Rate Responsive Pacing due to Electrocautery 总被引:3,自引:0,他引:3
NORBERT M. VAN HEMEL RUBEN P.H.M. HAMERLIJNCK KEES J. PRONK ED P. VAN DER VEEN 《Pacing and clinical electrophysiology : PACE》1989,12(11):1720-1723
Transient programmed upper limit stimulation (150 bpm) was observed during repetitively utilized electrocautery in the beginning of an open-heart surgical procedure in a patient with a minute ventilation rate responsive ventricular pacemaker. This tachycardia caused severe hemodynamic deterioration, and was also initiated by internal heart massage and manual ventilation. Considering the recommendations of the manufacturer, this series of serious events could have been prevented, when reprogramming to the inhibited mode had been executed in anticipation of the operation. 相似文献
82.
83.
84.
85.
Gold LS De Roos A J Ray RM Wernli K Fitzgibbons ED Gao DL Astrakianakis G Feng Z Thomas D Checkoway H. 《中国神经肿瘤杂志》2006,4(2):124-124
OBJECTIVES: This study assessed the associations between brain tumors and specific processes and exposures among female textile workers in Shanghai, China. METHODS: A case-cohort study was conducted that was nested in a cohort of textile workers originally included in a randomized trial of breast self-examination. Incident brain tumor cases (N=114) were identified from 1989 to 1998 from a tumor and death registry operated by the Shanghai Textile Industry Bureau. A subcohort (N=3188), representing an agestratified random sample of the entire cohort, was selected as a comparison group. 相似文献
86.
A patient who developed recurrent leukemia more than six years after marrow grafting from an HLA-identical same-sex sibling is reported. Difference in DNA restriction fragment length polymorphisms between donor and host demonstrated that the DNA in the recurrent leukemia sample was probably of donor origin. Possible mechanisms that could explain the long latent period between transplantation and expression of leukemic transformation are discussed. We conclude that future cases of late leukemic recurrence after marrow grafting should be studied to determine whether, in contrast to early relapses, late relapses occur in donor cells in most or all instances. 相似文献
87.
The Philadelphia (Ph1) chromosome, characteristic of chronic myelogenous leukemia (CML), arises from a reciprocal translocation between chromosomes 9 and 22. The site of the breakpoint on chromosome 22 is within a small region called the breakpoint cluster region (bcr). We have mapped the breakpoint within the bcr in peripheral blood leukocyte DNA from 22 Ph1-positive CML patients. No correlation between the site of the breakpoint and the clinical phase of the disease was found. However, a striking correlation between the site of the breakpoint and the length of time between presentation and onset of acute phase was observed: on average, patients with a 5' break-point had a fourfold longer chronic phase (median, 203 weeks) than those with a 3' breakpoint (median, 52 weeks). 相似文献
88.
E Lutgens M Daemen M Kockx P Doevendans M Hofker L Havekes H Wellens ED de Muinck 《Circulation》1999,99(2):276-283
BACKGROUND: This study documents (1) the progression of atherosclerosis along the entire arterial tree in APOE*3-Leiden mice after 1, 4, 6, 9, and 12 months of a high-fat/high-cholesterol (HFC) diet and (2) the amount and phenotype of DNA-synthesizing and apoptotic cells in different lesion types after 6 months of HFC diet. METHODS AND RESULTS: Diet duration was correlated with a craniocaudal progression of lesion development and with an increase in severity of the lesion. Typically, the lesions contained smooth muscle cells, macrophages, and T lymphocytes and were covered by an intact endothelium. Whereas DNA synthesis (BrdU uptake) was usually elevated in type II lesions (8.6+/-0.8% versus 1.0+/-0.2% in the nondiseased arterial wall; P<0.05), apoptosis was found primarily in advanced lesions (type IV, 1.3+/-0.1% and type V, 1.2+/-0.2% versus 0.04+/-0.04% in the nondiseased arterial wall [P<0.05]). Cell phenotyping revealed that the majority of DNA synthesis and apoptosis was confined to the macrophage-derived foam cell (68.6+/-3. 0% and 82.2+/-4.6%, respectively). CONCLUSIONS: This study shows that in APOE*3-Leiden mice, duration of an HFC diet is associated with (1) a craniocaudal progression of lesion development and (2) an increased complexity of atherosclerotic lesions. Furthermore, DNA synthesis is predominant in early lesions, whereas apoptosis is present mainly in more advanced lesions. Both parameters of cell turnover are confined primarily to the macrophage-derived foam cell. 相似文献
89.
Fefer A; Cheever MA; Thomas ED; Appelbaum FR; Buckner CD; Clift RA; Glucksberg H; Greenberg PD; Johnson FL; Kaplan HG; Sanders JE; Storb R; Weiden PL 《Blood》1981,57(3):421-430
Thirty-four patients aged 4-67 yr (median 17) with acute lymphocytic leukemia (ALL) (18 patients) or acute nonlymphocytic leukemia (ANL) (16 patients) who failed to enter complete remission (CR) or relapsed on conventional chemotherapy were treated with cyclophosphamide (CY), 60 mg/kg/day for 2 days, 1000 rad total body irradiation, and a marrow transplant from a genotypically identical normal twin. Sixteen of the patients received additional chemotherapy within the week before CY. After the transplant, 23 patients received immunotherapy consisting of killed autologous leukemic cells and/or normal twin peripheral blood lymphocytes, 16 as part of a prospectively randomized study. One moribund patient died before engraftment. Nine patients (6 ALL, 3 ANL) continued to have detectable leukemic cells. Twenty-four patients (70%) achieved CR. One of them died of viral hepatitis at 1 mo and another of viral interstitial pneumonitis at 4 mo in CR. Fourteen patients (7 ALL, 7 ANL) relapsed 2-16 mo (median 4) after transplantation. However, 8 patients (24%) (3 ALL, 5 ANL) remain in CR without any maintenance chemotherapy at 29-103 mo (median 80) after the transplant. The end results were not signficantly influenced by the type of leukemia, the immediated pre-CY chemotherapy, or the immunotherapy. The results show that this approach, even when applied to endstage patients with acute leukemia in relapse, causes tolerable morbidity, rare nonleukemic deaths, and frequent remissions, some of which represent cures. 相似文献
90.
Deborah J. Bowen PhD Eileen H. Shinn PhD Sophie Gregrowski Gretchen Kimmick MD MS Laura S. Dominici MD Elizabeth S. Frank ED M Karen Lisa Smith MD MPH Gabrielle Rocque MD MSPH Kathryn J. Ruddy MD MPH Teri Pollastro BS Michelle Melisko MD Tarah J. Ballinger MD Oluwadamilola M. Fayanju MD MA MPHS Antonio C. Wolff MD 《Cancer》2020,126(5):922-930
Members of the Translational Breast Cancer Research Consortium conducted an expert-driven literature review to identify a list of domains and to evaluate potential measures of these domains for inclusion in a list of preferred measures. Measures were included if they were easily available, free of charge, and had acceptable psychometrics based on published peer-reviewed analyses. A total of 22 domains and 52 measures were identified during the selection process. Taken together, these measures form a reliable and validated list of measurement tools that are easily available and used in multiple cancer trials to assess patient-reported outcomes in relevant patients. 相似文献